Navigation Links
Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
Date:3/30/2009

CHADDS FORD, Pa., March 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Nancy J. Hutson, Ph.D., to the company's board of directors. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions with that company, serving most recently as senior vice president, Pfizer Global Research and Development and director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories. Her appointment brings the number of Endo board members to nine.

Roger Kimmel, chairman of the board of Endo Pharmaceuticals, stated: "We are pleased to have Nancy Hutson join our board and bring her vast pharmaceutical knowledge and experience to our company. We welcome her contributions to our future success as we expand our product pipeline and therapeutic focus."

Dr. Hutson currently is a director of Cubist Pharmaceuticals, Inc. and Inspire Pharmaceuticals, Inc. and serves on the board of Planned Parenthood of Connecticut.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Mexico Biomedical Sensors Market - Growth, ... The Mexico Biomedical Sensors market ... CAGR of 2.68% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... Aug. 31, 2015 Trimb Healthcare AB ("Trimb") ... acquire YouMedical Group BV ("YouMedical"), a Dutch OTC company ... annual sales of approximately EUR 16 million, with solid ... "Our ambition is to build a leading international ... toward that goal. YouMedical gives us a stronger North ...
(Date:8/30/2015)... August 31, 2015 , ...   für chirurgische   Behandlung     ...   werden für eine   verheerende   Geburtsverletzung behandelt ... und die Anzahl ausgebildeter Chirurgen in Kenia bis 2017 ... heute bekannt, dass  Action on Fistula  seit ihrem Beginn ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... emerge in the world of pesticides and pest control, and ... implications for public health, ensure that this is done safely, ... in a new report. In a study published today ... , scientists from Oregon State University and the European Union ...
... announces that a new market research report is ... Synthetic Biology Industry http://www.reportlinker.com/p0305188/Global-Synthetic-Biology-Industry.html ... market for Synthetic Biology in US$ Million by ... Chemicals, Biotechnology & Pharmaceuticals, and Research & Development. ...
... PARK, N.J., Oct. 4 Shionogi Inc., the ... today announced the U.S. Food and Drug Administration ... extended-release tablets, an extended-release oral formulation for the ... children and adolescents ages 6-17 years. KAPVAY™ is ...
Cached Biology Technology:New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Reportlinker Adds Global Synthetic Biology Industry 2Reportlinker Adds Global Synthetic Biology Industry 3Reportlinker Adds Global Synthetic Biology Industry 4Reportlinker Adds Global Synthetic Biology Industry 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:8/28/2015)... , August 28, 2015 According ... Training Market by Assessment Type (Pen & Paper Based, ... Training, Corporate Learning, Academic Research), Vertical and Region - ... and Training Market to grow from USD 2.4 Billion ... a Compound Annual Growth Rate (CAGR) of 25.6% from ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... diesel engine is far from easy. Due to the ... cycles are the same. Furthermore, the measurements are difficult ... injected into the cylinder causes an extra source of ... with an engine adapted for this purpose. Laser ...
... compelling argument for reducing fish harvests the profit motive ... of lower catches for the long-term gain of higher returns ... on fisheries over-exploitation. They say their findings, published in ... cause of over-fishing industry opposition to lower catches ...
... Described as a hotspot of botanical diversity, there are ... Several thousand of them are used by traditional healers ... of problems from the common cold to serious diseases ... are will be the focus of The International Center ...
Cached Biology News:Economists: Reduce fish catch now for bigger net profits later 2Economists: Reduce fish catch now for bigger net profits later 3Study of African traditional medicine will begin world-first clinical trial 2Study of African traditional medicine will begin world-first clinical trial 3